source
- Novartis' Lutathera radioligand therapy may soon face first generic challengerNovartis has built a sizable business delivering radioligand therapies, with Lutathera being a leading product. A rival company is preparing to launch the first generic version, which could introd…
- Amneal to acquire biosimilar maker for $375 million upfrontAmneal Pharmaceuticals announced it will purchase a biosimilar development company, agreeing to pay $375 million in an upfront cash payment. The deal expands Amneal’s portfolio in the growing biosi…